Time to Fight the New with the Old—Old Antibiotics in New Role

Anuradha Vinod¹, Bhaskar Shenoy²

Abstract
Current medical practice is seeing a rise of multidrug-resistant bacteria because of inappropriate antibiotic usage. New antibiotics discoveries are not at par with the rapidly developing drug resistance. To tide over these circumstances, old antibiotics are now being revived researched and assigned new roles. Antibiotics, such as colistin, nitrofurantoin, polymyxin, etc., are used in nosocomial and critical care setting to tackle the multidrug-resistant bacteria. Even the use of old antibiotics should be pathogen centered and inappropriate use should be avoided. In this study, we are trying to throw some light on some of the old antibiotics which are currently in use and their efficacy. A lot of research is still required to optimize the drug dosing and prevention of side effects of these older antibiotics.

Keywords: Infections, Methicillin-resistant Staphylococcus aureus, Staphylococcus aureus.

Pediatric Infectious Disease (2020): 10.5005/jp-journals-10081-1242

The current medical practice involves use of a wide range of antibiotics for treating infections. The excessive and irrational use of antibiotics for mild illness has resulted in the emergence of a large number of resistant organisms especially which are resistant to a lot of commonly used antibiotics. Time and again practitioners are made aware of this emerging situation, and as days progress we will be devoid of all the available drugs as new antibiotic inventions are not keeping pace.¹ This is a very scary and difficult scenario when it comes to the treatment of patients with nosocomial infections, patients with underlying immunodeficiency, and patients in critical care units. As we are left with very few new antibiotic options, the need of hour is to bring in the old and forgotten antibiotics in new forms and new roles.

This is a very important step at this juncture through which we can keep the new and expensive antibiotics as reserve and also prevent the development of drug resistance.

Older antibiotics went behind curtains mainly because of reasons, such as side effects, palatability, difficulty in route of administration, and advent of more effective agents. Before using it in clinical settings, older antibiotics safety and efficacy should be reevaluated to optimize therapy.

The most advanced revived antibiotic now commonly used in present clinical practice is colistin. Other antibiotics, such as nitrofurantoin, doxycycline, etc., are also currently used for various gram-positive and gram-negative infections which are resistant to new drugs.

Polymyxins
Polymyxins are group of antibiotics which came into use in the 1940s and went into recluse after few years because of the neurotoxic and nephrotoxic side effects. Among the group of five compounds, polymyxin B and polymyxin E are used in clinical practice.⁷ They are bactericidal against gram-negative bacteria and not effective against majority of gram-positive bacteria and gram-negative coccı. Their use have resurfaced as they were shown to have in vitro activity against gram-negative bacteria, such as Klebsiella, Pseudomonas aeruginosa, Enterobacteriaceae, etc., which were resistant to the most commonly used antibiotics.

Colistin (Polymyxin E)
Colistin also known as polymyxin E came into clinical use in the 1950s and soon because of the neurotoxic and nephrotoxic side effects and the availability of other drugs with less side effects it went out of clinical usage.³ Recently, the focus on colistin has resurfaced because of its bactericidal effect on gram-negative bacteria majority of which are resistant to multiple antibiotics.

Spectrum of Action
Mainly bactericidal activity against major pathogenic gram-negative bacteria which are mainly involved in infections in immunocompromised, critical care settings, and patients with underlying chronic diseases like Enterobacteriaceae including extended spectrum beta-lactamase (ESBL) and carapenemase producing strains, such as Klebsiella pneumoniae, Acinetotabacter baumannii, and Pseudomonas aeruginosa. Antibacterial spectrum also includes other bacteria, such as Escherichia coli, Shigella, Salmonella, Bordetella, Haemophilus influenzae, etc.

Indications
Number of multicentric studies have proven efficacy and guarded safety of colistin in children, infants, and neonates mainly for highly resistant gram-negative infections which are resistant.
Nitrofurantoin has a broad spectrum of antibacterial action ranging from gram-negative bacteria, such as *E. coli*, *Klebsiella*, *Enterobacter*, *Shigella*, *Salmonella*, etc., to gram-positive organisms, such as *Staphylococcus aureus*, group *Streptococcus*, etc. The most important feature is that ESBL producing *E. coli* is also sensitive to nitrofurantoin, so it is mainly indicated for the treatment of lower urinary tract infections. 

**Spectrum of Activity**

Nitrofurantoin is a two-drug fixed combination antibiotic individually either of them are bacteriostatic together has a very broad spectrum of action against gram-positive bacteria including some methicillin-resistant *Staphylococcus aureus* (MRSA) and gram-negative bacteria like *Enterobacter*. The drug combination was introduced in 1969. The drug is also effective against *Toxoplasma gondii* isospora and *Pneumocystis jirovecii*. Due to the two-drug combination resistance development to drug is less. The main advantage of the drug was good oral availability and cost effectiveness and disadvantage was the allergic reaction in susceptible patients.

**Teicoplanin**

Glycopeptide group of antibiotics came into clinical use since 1978. It requires more research in children.

**Spectrum of Activity**

Action mainly against gram-positive organisms, active against both methicillin-resistant and methicillin-sensitive *S. aureus*, *S. pneumoniae*, enterococci, *Listeria, Corynebacterium, Clostridium*, and anaerobic gram-positive cocci. Oral absorption is poor. Indicated for the prevention of bacterial endocarditis in the presence of penicillin allergies. Also clinically used in catheter-related infections, cerebrospinal fluid (CSF), shunt infection resistant, bone and soft tissue infection. Mainly reserved for the patients with neutropenia along with beta-lactam and aminoglycosides. Advantages when compared to vancomycin are single daily dosage, intramuscular administration, etc. Side effects are mainly rashes, drug-related fever, and dosage adjustment to be made in renal impairment.
Fosfomycin has a broad spectrum of action and excellent safety profile with little or limited research in pediatrics. The drug is noted to have very good dissemination into tissues like bones.

**Spectrum of Activity**

Antibacterial spectrum include MRSA, multirud-drug-resistant gram-negative bacteria (carbapenem-resistant Enterobacteriaceae), *Staphylococcus epidermidis*, *Listeria*, and resistant *Pneumococcus*. Fosfomycin is currently being researched for community-acquired lower urinary tract infections in pediatrics.16

**Doxycycline**

Doxycycline, a second generation tetracycline, came into clinical use since early 1970s. Uses in children were limited due to the side effects of discoloration of teeth. Recently, studies have proved against this and now doxycycline is recommended for shorter duration therapy even in children less than 8 years.

**Spectrum of Activity**

Doxycycline exhibits bacteriostatic effect on a large number of gram-positive and gram-negative bacteria parasites, etc., of which *Brucella*, *Bartonella*, *Enterobacter*, *Gonococc*, *Vibrio cholerae*, *Bacillus anthrax*, *Listeria*. Other organisms, such as *Rickettsia*, *Mycoplasma*, *Chlamydia*, etc., require special mention. It is considered as a first-line therapy in rickettsial illness in any age group. Also used in trachoma, psittacosis, relapsing fever, etc. Recently, doxycycline is used for macrolide-resistant *Mycoplasma* infections. In scenarios of resistant gram-negative infections, if culture sensitive then doxycycline is used. Use in cholera and prophylaxis for falciparum malaria also found to be effective.17 Due to its intracellular mechanism of activity recently approved safety profile and low cost, the demand of doxycycline in clinical practice has increased.18 Over use of this drug should be avoided and should be used only in recommended and culture proven conditions. Photosensitivity, *C. difficile* infection, and teeth discoloration on prolonged use and availability in the form of capsules are major disadvantages.

**Temocillin**

Temocillin, a semisynthetic penicillin derivative, came in 1980s did not see much clinical use due to its narrow antibacterial spectrum, mainly lack of action against gram-positive bacteria. The current rise of resistant gram-negative bacteria resulted in renewed interest in temocillin which has excellent beta-lactamase and carbapenemase stability.

**Spectrum of Activity**

As mentioned earlier, temocillin has a narrow spectrum of activity mainly against gram-negative bacilli, such as *E. coli*, *Klebsiella*, *Enterobacter* sp., etc. The clinical need of temocillin is its effectiveness against resistant Enterobacteriaceae4 and helps in preserving carbapenems. Temocillin proved to be effective and safe in the treatment of pyelonephritis often due to ampicillin-resistant strains in children according to a study by Verboven.19 Further studies in pediatrics is required now, as of limited studies the drug is mainly used in hepatic transplant recipients, resistant urinary infections, and cholangitis.

Many other old antibiotics, such as spectinomycin, minocycline, quinupristin–dalfopristin, fusidic acid, etc., are being extensively revived researched in adults.

Rational use of old antibiotics in clinical practice paves a new way in the treatment of multidrug-resistant pathogens which is very much pronounced in the critical care and nosocomial setting and slowly expanding into community. The old drugs also help in preserving the new and expensive drugs, so that we are better equipped in our fight against the microbes. Antibiotic stewardship is the current norm and must be followed in all clinical settings.

**REFERENCES**

1. Cassir N, Rolain J-M, Brouqui. P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014;5:551. DOI: 10.3389/fmicb.2014.00551.

2. Gupta S, Govil D, Karak PN, et al. Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med 2009;13(2):49–53. DOI: 10.4103/0979-5229.56048.

3. Celebi S, Hacimustafaoglu M, Koksal N. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int 2010;52(3):410–414. DOI: 10.1111/j.1442-200X.2009.03015.x.

4. Iosifidis E. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010;169(7):867–874. DOI: 10.1007/s00431-009-1137-3.

5. Jajoo M, Muralidhara C, Balasubramanian V. Colistimethate sodium use in neonates. Pediatr Infect Dis J 2011;30(3):218–221. DOI: 10.1097/INF.0b013e3182064be6.

6. Flagas ME. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009;33:503.e1–50a3.e13.

7. Falagas ME. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009;28(2):123–127. DOI: 10.1097/INF.0b013e31815855bd.

8. Tamma PD, Newland JG, Pannaraj PS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013;32(1):17–22. DOI: 10.1097/INF.0b013e3182703790.

9. Siddiqui NR, Qamar FN, Jurair H, et al. Multi-drug resistant gram-negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. BMC Infect Dis 2014;14(1):626. DOI: 10.1186/s12879-014-0626-9.

10. Huttner A, Verhaegh EM, Harbarch, S., et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials, Mouton. J Antimicrob Chemother 2015;70(9):2456–2464. DOI: 10.1093/jac/dkv147.

11. Masters PA, O’Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163(4):402–410. DOI: 10.1001/ archinte.163.4.402.

12. Clindamycin: new look at an old drug. Infectious Diseases in Children, January 2005.

13. Doern GV. Antimicrobial resistance among clinical isolates of streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agent Chemother 2001;45(6):1721–1729. DOI: 10.1128/AAC.45.6.1721-1729.2001.

14. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investigat Drugs 2006;7(8):740–749.

15. Jeya M, Moon HJ, Lee KM, et al. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Curr Pharm Biotechnol 2011;12(9):1194–1204. DOI: 10.2174/138920211796173832.

16. Baquero-Artigao F, del Rosal Rabes T. Fosfomycin in the pediatric setting: evidence and potential Indications. J Spanish Soc Chemother 2019;32(Suppl 1):55–61.

17. Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation? Expert opinion. Drug Saf 2016;15(3):367–382. DOI: 10.1517/14740211.2016.113584.

18. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005;27(9):1329–1342. DOI: 10.1016/j.clinthera.2005.09.005.

19. Verboven M, Lauwers S, Pintens H. Temocillin in the treatment of pyelonephritis in children. Drugs Exp Clin Res 1987;11(3):171–173.